

Aurobindo drug gets US FDA nod

OUR BUREAU

Hyderabad, January 11

Drug firm Aurobindo Pharma Ltd has received approval from the US Food and Drug Administration (USFDA) to manufacture and market Norethindrone Acetate tablets.

The approved Abbreviated New Drug Application (ANDA) is a bioequivalent and therapeutically equivalent to the reference listed drug product Aygestin of Duramed Pharmaceuticals. It is used in the treatment of endometriosis, uterine bleeding caused by abnormal hormone levels and secondary amenorrhea, the Hyderabad-based company said in a release. The approved product has an estimated market size of \$24 million for the 12 months ended November 2015, according to IMS.

Aurobindo's scrip lost 1.40 per cent on the Bombay Stock Exchange on Monday to close at ₹834.30.

Company